Therapeutic targeting of oncogenic transforming growth factor-β1 signaling by antisense oligonucleotides in oral squamous cell carcinoma

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 539-544

  Kim, Seong Gon ^a   Song, Ji Young ^b  

^a Gangneung Wonju National University   (South Korea)

^b Jeju National University College of Medicine   (South Korea)

Author keywords

Antisense; Matrix metalloproteinase 2; Squamous cell carcinoma; Transforming growth factor 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLINE; GELATINASE A; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PROLIFERATING CELL NUCLEAR ANTIGEN; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TONGUE NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863476082     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1811     Document Type: Article

References (26)

1. Kim ES, Kies M and Herbst RS: Novel therapeutics for head and neck cancer. Curr Opin Oncol 14: 334-342, 2002. (Pubitemid 34492868)
2. Hong SD, Hong SP, Lee JI and Lim CY: Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol 36: 207-213, 2000.
3. Lionetti P, Pazzaglia A, Moriondo M, et al: Differing patterns of transforming growth factor-β expression in normal intestinal mucosa and in active celiac disease. J Pediatr Gastroenterol Nutr 29: 308-313, 1999. (Pubitemid 30366140)
4. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G and Gress TM: TGF-β-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204-211, 2001. (Pubitemid 32574276)
5. Sier CFM, Kubben FJGM, Ganesh S, et al: Tissue level of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417, 1996. (Pubitemid 26254571)
6. Wakefield LM and Roberts AB: TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22-29, 2002. (Pubitemid 34094985)
7. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
8. Kovasc EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 12: 17-23, 1991.
9. Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573, 1993.
10. Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999. (Pubitemid 129519680)
11. Kim SG, Kim MH, Chae CH, Jung YK and Choi JY: Downregulation of matrix metalloproteinases in hyperplastic dental follicles results in abnormal tooth eruption. BMB Rep 41: 322-327, 2008. (Pubitemid 351656928)
12. Kim JY, Rotaru H and Kim SG: The clinical significance of the expression of TGF-β1 and MMP-2 related to the regional lymph node metastasis in the oral squamous cell carcinoma. J Korean Oral Maxillofac Surg 33: 199-203, 2007.
13. Park YW, Kim SG, Choi JY and Lee SK: Recapitulating orthotopic tumor model through establishment of a parotid gland tumor with lung metastasis using HeLa cell injection into nude mice. Oncol Rep 23: 701-708, 2010.
14. Carlsson G, Gullberg B and Hafström L: Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105: 20-23, 1983. (Pubitemid 13194363)
15. Roberts AB and Sporn MB: The transforming growth factors. In: Peptide Growth Factors and their Receptors I. Sporn MB and Roberts AB (eds). Springer, Berlin, pp419-472, 1990.
16. Prime SS, Matthews JB, Patel V, et al: TGF-β receptor regulation mediates the response to exogenous ligand but is independent of the degree of cellular differentiation in human oral keratinocytes. Int J Cancer 56: 406-412, 1994.
17. Aiping H: Drug resistance and gene amplification potential regulated by transforming growth factor β1 gene expression. Cancer Res 55: 1758-1762, 1995.
18. Yingling JM, Blanchard KL and Sawyer JS: Development of TGF-β signaling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022, 2004. (Pubitemid 39642364)
19. Moore LD, Isayeva T, Siegal GP and Ponnazhagan S: Clin Cancer Res 14: 4961-4970, 2008.
20. Woolf TM, Melton DA and Jennings CGB: Specificity of an antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 89: 7305-7309, 1992.
21. Thierry AR, Rahman A and Dritschilo A: Liposomal delivery as a new approach to transport antisense oligonucleotides. In: Gene Regulation: Biology of Antisense RNA and DNA. Erickson R and Izant JF (eds). Raven Press Ltd., New York, pp147-161, 1992.
22. Cheng K, Yang N and Mahato RI: TGF-β1 gene silencing for treating liver fibrosis. Mol Pharm 6: 772-779, 2009.
23. Wilkins-Port CE and Higgins PJ: Regulation of extracellular matrix remodeling following transforming growth factor-beta1/ epidermal growth factor-stimulated epithelial-mesenchymal transition in human premalignant keratinocytes. Cells Tissues Organs 185: 116-122, 2007. (Pubitemid 46956852)
24. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr and Chatterjee SK: Tumor metastasis is an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells. J Cell Biochem 97: 1036-1051, 2006.
25. Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V and Munshi HG: Transforming growth factor-β1 promotes matrix metalloproteinase-9- mediated oral cancer invasion through Snail expression. Mol Cancer Res 6: 10-20, 2008. (Pubitemid 351378162)
26. Munshi HG, Wu YI, Mukhopadhyay S and et al: Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta 1-induced pericellular collagenolysis. J Biol Chem 279: 39042-39050, 2004. (Pubitemid 39296066)